Company

NuRx Pharmaceuticals

As of the edition of 20 October 2026, NuRx Pharmaceuticals runs 1 drug; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Stopped1
Total1

Where it needs a new molecule

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
TargetRoute
RXRA Retinoic acid receptor RXR-alphaRoute A
RXRB Retinoic acid receptor RXR-betaRoute A
RXRG Retinoic acid receptor RXR-gammaRoute A

All 3 rows on route A or B

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Cancer: 1 trials led
  • Lungs and airways: 1 trials led